Anchor Investment Management’s TG Therapeutics TGTX Stock Holding History

Anchor Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$258K	Hold	4,700	–	–	0.02%	351
2026 Q1	$156K	Hold	4,700	–	–	0.01%	414
2025 Q4	$140K	Hold	4,700	–	–	0.01%	428
2025 Q3	$170K	Hold	4,700	–	–	0.01%	407
2025 Q2	$169K	Hold	4,700	–	–	0.01%	397
2025 Q1	$185K	Hold	4,700	–	–	0.02%	371
2024 Q4	$141K	Hold	4,700	–	–	0.01%	416
2024 Q3	$110K	Hold	4,700	–	–	0.01%	450
2024 Q2	$83.6K	Hold	4,700	–	–	0.01%	454
2024 Q1	$71.5K	Hold	4,700	–	–	0.01%	490
2023 Q4	$80.3K	Hold	4,700	–	–	0.01%	467
2023 Q3	$39.3K	Buy	+4,700	New	+$65.5K	0.01%	547

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Anchor Investment Management's TGTX Position: Q2 2026 in Review

Anchor Investment Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 4,700 shares worth $258K. The position accounts for 0.02% of the portfolio, ranked #351.

Anchor Investment Management first reported a position in TGTX in Q3 2023 and has held it in 12 quarters since. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Anchor Investment Management held 4,700 shares of TG Therapeutics worth $258K as of Q2 2026.
Anchor Investment Management left its TG Therapeutics share count unchanged in Q2 2026.
TG Therapeutics made up 0.02% of Anchor Investment Management's portfolio in Q2 2026, its #351 holding.
Anchor Investment Management first reported a position in TG Therapeutics in Q3 2023 and has held it in 12 quarters since.
430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Anchor Investment Management's 13F filing for Q2 2026, filed 15 Sep 2026.